• Listed Companies
  • Announcements
  • TIANJIN DEV
  • EN
  • 繁
  • 简
  • Oct 30, 2023
    12:03

    Unaudited Financial Results for the nine months ended 30 September 2023 of Tianjin Lisheng Pharmaceutical Co., Ltd.

    Results of a Subsidiary

    00882 - TIANJIN DEV


  • Oct 10, 2023
    17:34

    Discloseable and Connected Transaction - Disposal of 15% Equity Interest in Tianjin Pharmaceutical Group Finance Co., Ltd. held by Tianjin Lisheng Pharmaceutical Co., Ltd.

    Connected Transaction

    00882 - TIANJIN DEV


  • Sep 29, 2023
    12:08

    List of Directors and their Roles and Functions

    List of Directors and their Role and Function

    00882 - TIANJIN DEV


  • Sep 29, 2023
    12:05

    Change of Executive Director and General Manager and Change of Authorised Representative

    Change in Directors or of Important Executive Functions or Responsibilities

    00882 - TIANJIN DEV


  • Aug 30, 2023
    12:19

    Interim Dividend for the six months ended 30 June 2023

    Dividend or Distribution (Announcement Form)

    00882 - TIANJIN DEV


  • Aug 30, 2023
    12:13

    Announcement of Interim Results for the six months ended 30 June 2023

    Closure of Books or Change of Book Closure Period

    00882 - TIANJIN DEV


  • Aug 25, 2023
    06:12

    Potential Disposal of 15% Equity Interest in Tianjin Pharmaceutical Group Finance Co., Ltd. held by Tianjin Lisheng Pharmaceutical Co., Ltd.

    Inside Information

    00882 - TIANJIN DEV


  • Aug 25, 2023
    06:10

    Unaudited Financial Results for the six months ended 30 June 2023 of Tianjin Lisheng Pharmaceutical Co., Ltd.

    Results of a Subsidiary

    00882 - TIANJIN DEV


  • ‹
  • 1
  • 2
  • ...
  • 8
  • 9
  • 10
  • ...
  • 57
  • 58
  • ›
  • »

Address

1/F, China Building,
29 Queen's Road Central, Hong Kong
(852) 3693 2688
info@cre8corp.com

Sitemap

  • Listed Companies
  • Disclaimer
  • Privacy Policy

Newsletter

Fill your email and sign up for monthly newsletter to keep updated

© Cre8ir 2025 All right reserved.